Grifols (GIKLY) Receivables (2009 - 2025)
Grifols (GIKLY) posted Receivables of $875.4 million for Q4 2025, up 4.62% quarter-over-quarter from $836.7 million in Q4 2024, and up 4.62% year-on-year from $836.7 million in Q4 2024.
Grifols (GIKLY) Receivables (2009 - 2025) Analysis & Trends
Grifols (GIKLY) has reported Receivables for 16 consecutive years, with $875.4 million the latest figure, recorded in Q4 2025.
- Receivables for Q4 2025 came in at $875.4 million, up 4.62% year-over-year; the trailing twelve-month figure through Dec 2025 was $875.4 million (up 4.62% YoY), and the FY2025 annual result was $875.4 million, up 4.62% from the prior year.
- Receivables was $875.4 million for Q4 2025 at Grifols, up from $836.7 million in the prior quarter.
- Over five years, Receivables peaked at $875.4 million in Q4 2025 and troughed at $647.4 million in Q4 2021.
- Average Receivables over 5 years is $802.8 million, with a median of $828.7 million recorded in 2022.
- Year-over-year, Receivables grew 28.01% in 2022 and dropped 0.31% in 2023.
- Over 5 years, Receivables stood at $647.4 million in 2021, then climbed by 28.01% to $828.7 million in 2022, then decreased by 0.31% to $826.1 million in 2023, then increased by 1.28% to $836.7 million in 2024, then grew by 4.62% to $875.4 million in 2025.
- Per Business Quant data, the three most recent Receivables figures were $875.4 million in Q4 2025, $836.7 million in Q4 2024, and $826.1 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 21.18 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 17.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 12.48 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 12.21 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 9.14 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 5.33 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 12.59 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | 875.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 875.36 Mn |
| Dec 31, 2024 | 836.71 Mn |
| Dec 31, 2023 | 990.76 Mn |
| Dec 31, 2022 | 828.67 Mn |
| Dec 31, 2021 | 645.16 Mn |
| Dec 31, 2020 | 543.20 Mn |
| Dec 31, 2019 | 500.65 Mn |
| Dec 31, 2018 | 412.71 Mn |
| Jun 30, 2018 | 380.89 Mn |
| Dec 31, 2017 | 384.88 Mn |
| Jun 30, 2017 | 429.83 Mn |
| Dec 31, 2016 | 576.36 Mn |
| Sep 30, 2016 | 439.07 Mn |
| Jun 30, 2016 | 561.65 Mn |
| Dec 31, 2015 | 463.58 Mn |
| Sep 30, 2015 | 540.53 Mn |
| Jun 30, 2015 | 524,956.47 |
| Mar 31, 2015 | 624.56 Mn |
| Dec 31, 2014 | 670.10 Mn |
| Sep 30, 2014 | 757.88 Mn |